secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001193125-24-048027
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci reports prelim FY2023 revenue $5.7M, cash $97.7M; proposes public offering
--------------------------------------------------------------------------------

- Preliminary Q4 revenue ~$0.3M, FY revenue ~$5.7M; operating expenses $120-122M incl $21.3M goodwill impairment.
- Unrestricted cash/short-term investments $97.7M as of Dec 31, 2023.
- Filed preliminary prospectus for underwritten public offering of common stock (undisclosed size).
- 16 Active Programs with partners including AstraZeneca, Almirall, Merck; ABS-101 IND submission planned Q1 2025.
- ABS-101 IND-enabling studies started Feb 2024; Phase 1 potentially H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000119312524048027/0001193125-24-048027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000119312524048027/d800047d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-048027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer